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V ascular anomalies (VAs) are a heterogeneous group of disorders originating from blood and/or lympha tic vessels that are further classified as either vascular malformations (VMs) or vascular tumours (VTs) (1) . VTs are thought to result from endothelial proliferation. They include infantile and congenital haemangiomas, tufted angiomas and kaposiform haemangioendotheliomas (KHE) (2) . In contrast, VMs are anomalies resulting from abnormal embryonic morphogenesis of blood and/ or lymphatic vessels and have a normal endothelial cell turnover. They are described by the abnormal vessel type(s). VMs are generally present at birth; they enlarge through expansion that is proportionate to the child's growth, as well as in response to infection, hormonal changes or trauma (3) (4) (5) .
Although the majority of VAs are benign and cause minor symptomatology, some may be associated with complications. Growth and/or expansion of VAs can cause clinical problems, such as disfigurement, chronic pain, recurrent infections, coagulopathies, organ dysfunc tion and death. Individuals often experience progressive clinical symptoms with a worsening quality of life (6) .
Treatment of VAs is largely based on symptoms, and no therapy is suggested as a first possibility. Histori cally, VMs have been primarily treated by procedural interventions to achieve local control, such as excision, embolization, sclerotherapy, debulking and pulsed dye laser. In contrast, treatments of VTs have been based mostly on medical therapy; infantile haemangiomas are mostly treated with propranolol when indicated, whereas other VTs might be treated with steroids, vincristine, interferon, chemotherapeutic agents or radiotherapy or surgery (7, 8) . Nevertheless, some of these complicated VAs are refractory to the abovementioned treatment modalities. In these cases, rapamycin (mTOR) inhibitors are found to be more promising (9) (10) (11) (12) (13) (14) (15) (16) .
mTOR is a serine/threonine kinase regulated by phosphoinositide 3 kinase (PI3K) and protein kinase B (Akt). The PI3K/AKT/mTOR pathway acts as a master switch on numerous cellular processes, including cellular catabolism and anabolism, cell motility, angiogenesis and cell growth (17) . Enhanced mTOR signalling increases expression of the vascular endothelial growth factor (VEGF), a key regulator of angiogenesis and lymph angiogenesis (18) . Disorders that lead to inappropriate activation of the PI3K/AKT/mTOR pathway result in tissue overgrowth in association with VAs (6) . mTOR inhibitors, such as sirolimus, directly inhibit mTOR, therefore blocking downstream protein synthesis and subsequent cell proliferation and angiogenesis (17) .
Sirolimus is effective for treatment of VAs in syndro mes with an upregulated mTOR activity, specifically for hamartomas in patients with PTEN mutations (19) (20) (21) , VTs in patients with tuberous sclerosis (22) and in pa tients with lymphangioleiomyomatosis (LAM) (23, 24) . Given its effectiveness in these conditions, sirolimus was initially tried as a VA treatment in a patient with refrac tory KHE with KasabachMerritt phenomenon (KMP) (25) . This patient had a rapid and dramatic response to sirolimus treatment. Since this initial success, the use of sirolimus has expanded rapidly (8) . While initially explored for KHE and lymphatic malformation (LM) (26) (27) (28) , sirolimus is now being used broadly throug hout the VA spectrum and is showing promising results in both systemic administration (10, (29) (30) (31) and topical administration (32) (33) (34) .
Sirolimus opens the era of targeted molecular therapy for complicated VAs (35, 36) . The discovery of muta tions that upregulate the PI3K/Akt/mTOR pathway and result in VAs, such as PTEN (37), PIK3CA (38, 39) , TIE2 (40), RASA1 (41) and NRAS (42) , provides the molecular rationale for mTOR inhibition in many of the VA disorders and sets the stage for targeting genes and pathways involved in VAs to be developed (6) .
In recent years, several case reports (11, 15, (43) (44) (45) (46) (47) (48) and retrospective case series (12, 14, 29, (49) (50) (51) (52) have been published on the use of sirolimus for the treatment of VAs, with positive results. Following these publi cations, sirolimus was further evaluated in a phase II study of 60 patients with complicated VAs, with clinical improvement in most patients and with tolerated adverse effects (6) . However, an uptodate literature review that addresses these publications, characterizes clinical features and assesses the efficacy and safety of sirolimus for different VAs, is lacking.
Therefore, the objective of this study is to evaluate the efficacy and safety of sirolimus in the treatment of child ren and young adults with complicated VAs. We present here a series of young adults, children and neonates with complex VAs treated with sirolimus in 3 medical centres in Israel, and a literature review.
METHODS
A retrospective review was performed on 19 cases of complicated VAs treated with sirolimus between March 2013 and December 2017. Fifteen patients were treated at the Sheba Medical Centre, 3 were treated at the Hadassah Medical Centre, and one was treated at the Shaare Zedek Medical Centre. Oral sirolimus was adminis tered to 17 patients, while topical sirolimus was administered to 2 patients. The systemic treatment regimen initially consisted of oral 0.6 mg/m 2 sirolimus twice daily, which was then titrated to reach a target level of 5-12 ng/ml. The topical treatment regimen consisted of a twice daily application of 0.2% sirolimus gel. A positive response to treatment was defined as a clinical/radiological stabilization or a decrease in lesion size, overgrowth, malformation weeping and/or bleeding, decreased number of thrombosis events, resolution of transfusion requirements, decreased number of cel lulitis episodes, improvement in quality of life and/or functional impairment and a reduction in pain, as reported by the patients. A partial response was defined as an improvement in the symptoms and a reduction in the lesion, but a persistence of the anomaly. A complete response was defined as a resolution of symptoms and lesion. Laboratory parameters that were monitored included, but were not limited to, complete blood count (CBC), liver function tests, serum creatinine and lipid profile. Appropriate imaging studies were obtained throughout the study, when indicated. The case series, with review of the medical record, was approved by each Institutional Review Board.
Concurrently, a review of the literature was performed using the MEDLINE database via PubMed for publications on sirolimus treatment for VAs, without date or language limitations. The follo wing key words were used in various combinations: "rapamycin", "sirolimus", "mTOR inhibitor", "vascular", "malformations", "tumours". The inclusion criteria were: English language and the relevance of the title or abstract to the field of research, including VTs and VMs treated with systemic sirolimus in humans. Exclu sion criteria were: studies describing single patient case reports, malignant tumours, sirolimus administered in the form of neoad juvant/adjuvant therapy and topical treatment. For each selected report, the following variables were considered: year and country of publication, journal, study design, number of cases described, sex and age of the patients, symptoms, type of the VA, treatment (including dosage and target serum level, efficacy, toxicity) and followup. Subsequently, a descriptive analysis was performed. Since efficacy criteria were heterogeneous, sirolimus treatment was considered to be efficient if the authors reported it as such. The efficiency rate (calculated as the percentage of patients who had a positive response to Sirolimus treatment out of the total number of patients receiving Sirolimus treatment) of sirolimus was then calculated. Two reviewers first selected the studies and then extracted and classified the data. Another independent reviewer checked the selection and the data classification.
RESULTS

Patient characteristics
Nineteen patients with different VAs were included in this report. Eighteen had malformations: congeni tal, lipomatous, overgrowth, vascular malformations, epidermal naevi and spinal/skeletal anomalies and/or scoliosis (CLOVES) syndrome n = 2, KlippelTrenaunay syndrome (KTS) n = 5, ParkesWeber syndrome (PWS) n = 1, combined lymphaticvenous malformation (LVM) n = 2, lymphatic malformation (LM) n = 4, blue rubber naevus syndrome (BRBNS) n = 1, arteriovenous mal formation (AVM)/PTEN n = 1, generalized lymphatic anomaly (GLA) (n = 2), and 1 patient had VT (unknown n = 1). Male predominance (2.17:1) existed, and the mean age at the time of treatment initiation was 6.2 years (range 0.5-322 months). Thirteen patients (68%) were pretreated prior to sirolimus, all with at least 1 surgical or interventional procedure performed. Although some of the patients had shown a partial response to prior in terventions and medical therapy, all patients continued to experience debilitating or lifethreatening complications, including chronic pain (79%), overgrowth (42%), coa www.medicaljournals.se/acta gulopathies (37%), recurrent cellulitis (16%), secretions (26%) and organ dysfunction (37%).
Response
Clinical improvement was demonstrated in 15 patients (79%) and included an improvement in pain level, size of VAs, secretion, as well as decreased cellulitis and throm bosis events. One patient (Patient 1) with CLOVES had a nearly complete resolution of cystic lesions and overgrowth, as shown in Fig. 1 . Only 2 patients (Patient 7 with KTS and Patient 8 with PWS) had shown a poor response to overgrowth and discontinued treatment. Two patients with GLA (Patients 17 and 18) had a par tial response expressed in respiratory stabilization for several months, before further deterioration due to their underlying disease. Patient 18 eventually died from re spiratory failure while on sirolimus treatment. The mean initial response time was 1.5 months (range 10-90 days), except for Patient 14, for whom data were not available, and for Patients 7 and 8, who showed no response. The mean followup time was 19.42 months (range 1.5-60 months). Fourteen patients (74%) discontinued treatment with sirolimus during followup. In 10 of these patients (71%), exacerbation was demonstrated after disconti nuing sirolimus treatment, whereas improvement was evident following the renewal of it. In total, 15 patients are now on continuous sirolimus treatment and 1 patient (Patient 10) is on pulse therapy, as needed. Details of the sirolimus treatment courses are shown in Table I .
Toxicity
Adverse effects observed in this study were consistent with expected sirolimus toxicities. Sirolimus toxicities were graded according to the Common Terminology Criteria for Adverse Events. Observed effects inclu ded Grade I hypercholesterolemia (n = 3), Grade I-III hyper triglyceridaemia (n = 2), Grade I elevation of liver enzymes (n = 4), Grade I mouth sores (n = 1), Grade I thrombocytopaenia (n = 2) and Grade I abdominal pain and nausea (n = 1). In addition, adverse effects that are possibly attributable to sirolimus treatment included thrombocytosis (n = 2), Grade III hyperkalaemia (n = 1), perianal abscess (n = 1) and buttocks abscess (n = 1). Six patients experienced bacterial infection during treat ment, including cellulitis (n = 4), pneumonia (n = 1) and methicillinresistant Staphylococcus aureus (MRSA) bacteraemia (n = 1). One patient developed an opportu nistic cytomegalovirus (CMV) infection (n = 1). Only 2 patients interrupted sirolimus therapy due to adverse events possibly attributable to sirolimus treatment; one experienced hyperkalaemia and the other an elevation of liver enzymes. Both of them resumed sirolimus therapy shortly after stopping. Four other patients had brief inter ruption of sirolimus treatment due to intercurrent febrile disease. All other adverse events were managed without treatment interruption. None of the patients developed neutropaenia during followup.
Literature review
Of the 304 articles identified in the literature search, 7 retrospective case series (13, 15, 29, (41) (42) (43) (44) ) and 1 phase II study (7) were included, corresponding to 90 and 60 patients, respectively. Sex distribution included 73 (49%) females, 58 (38%) males and for 19 patients (13%) the sex was not reported. Regarding the age at which siroli mus treatment began, no data on compatible stratification were available for 101 patients and therefore we referred to the median age as reported. The majority of patients (80%) started sirolimus treatment between 2-13 years of age. Among the VAs presented in this review, 19% (n = 29) were VTs, mostly KHE/tufted angioma, and 81% (n = 121) were VMs, mostly LMs. All patients had severe symptoms before sirolimus treatment was started, which were detailed in 49 cases: 17 (35%) had coagulopathies, 13 (27%) experienced organ dysfunction, 9 (18%) had chronic pain, 4 (8%) had overgrowth, and 7 (14%) had recurrent cellulitis.
Oral sirolimus treatment was administered to all patients. A starting dose of sirolimus, 0.8 mg/m 2 twice daily, was administered orally to most patients (96%), while for the remaining 4% the starting dose was 0.05 mg/kg twice daily. The sirolimus target serum level was heterogeneous. In 62% of patients the levels were maintained between 10 and 15 ng/ml, in 8% the target level was 5-15 ng/ml and in 27% data were not repor ted. Most of the patients reported in this review (72%) were still taking sirolimus at the endpoint of each study. Sirolimus therapy was withdrawn in 40%. Of these, 30% had worsened after the withdrawal and therefore restarted therapy. Criteria considering the efficacy of the treatment were variable and included clinical, radiological, laboratory, quality of life related or combined criteria. Clinical crite ria were diverse and included a stabilization or decrease in the lesion size, a reduction in transfusion requirements, an improvement in pain level, decreased events of cel lulitis, and improved vital functions. The most common radiological evaluation was magnetic resonance imaging (MRI) performed according to a standardized protocol. Computer tomography (CT) scans and radiographs were also considered for efficacy criteria. Laboratory criteria included haemoglobin, platelets, fibrinogen and D-dimer levels. Healthrelated quality of life (HRQoL) was asses sed using scales, mostly the Paediatric Quality of Life Inventory 4.0. In this review, sirolimus was found to be efficient in 85% of cases, including 5 cases of complete remission (CR). The median response time was 7.9 weeks (range 1-90 weeks) for 59 cases, while in 91 cases the data were not reported.
Overall, in this review sirolimus was well tolerated with easily manageable adverse effects. The most com monly reported adverse effects attributed to the sirolimus treatment included gastrointestinal (28%), blood/bone marrow (22%), metabolic/laboratory (16%) and muco sitis (13%). Only 6 patients (4%) interrupted treatment due to adverse effects, which included neutropaenia, elevation of liver enzymes, nausea interfering with the quality of life, persistent lymphoedema, a brief inter ruption for intravenous (IV) antibiotics and associated alopecia, each in a single patient. Four of these patients resumed treatment after stopping sirolimus therapy. The characteristics and responses of 150 patients included in this review are shown in Table II .
DISCUSSION
This study is a retrospective case series report on the use of sirolimus for the treatment of complicated Vas, and a literature review. Data were assessed for 19 patients and for 150 patients, respectively. To the best of our know ledge, this paper is the largest review study referring to the use of sirolimus treatment for VA, with the aim of characterizing the demographics and clinical features of the patients, as well as assessing the sirolimus treatment efficacy and safety in different VAs.
In this retrospective study, more favourable responses to sirolimus were seen in younger patients. Five patients (26%) started sirolimus treatment before the age of 2 months. All 5 patients had a good response to sirolimus treatment. Dramatic response was demonstrated in 4 patients, including a nearly complete resolution in 1 pa tient with CLOVES syndrome. In our literature review, 5 patients reported starting with sirolimus treatment before the age of 2 months. All had a good response to sirolimus, with 3 of them achieving complete remission. Sirolimus was also very efficient in a group of young patients (n = 15) who started therapy between the ages of 2 months and 2 years, with 100% partial response and 1 complete response. Furthermore, it was previously suggested that younger patients may respond better than older patients (7, 15) . Our experience also suggests that the early use of sirolimus should be considered in order to reduce morbidities associated with the VAs, invasive interventions and to improve prognosis.
In our retrospective study, 79% of patients (n = 15) with VAs exhibited beneficial overall responses to si rolimus, including patients with CLOVES syndrome, In this literature review, oral sirolimus therapy was administered to all patients. In our retrospective review, 17 of the patients were treated orally, while 2 were trea ted with topical sirolimus (KTS n = 1, LVM n = 1). The 2 cases treated with a topical application of sirolimus responded very well, probably due to the presence of superficial lymphatic components, and without any reported adverse effects. To the best of our knowledge, this is the first reported case of a successful use of topical sirolimus for the treatment of KTS (with CLVM) and LVM. From reports to date, the topical use of sirolimus was found to be beneficial for LM cases and was studied in combined therapy with pulsed dye laser for capillary malformations (32) (33) (34) . It was suggested previously that percutaneous delivery of the mTOR inhibitors may allow for an effective longterm therapy, while avoiding syste mic toxicities (32) . Indeed, from our limited experience, it appears that the topical use of sirolimus in cases of the VMs with lymphatic components, such as the LVM and CLVM, and not only in cases of pure LMs, is both efficient and safe.
In both retrospective study and literature review, most patients were still taking sirolimus at the endpoint of the study. As of today, there are no guidelines that determine the duration of sirolimus therapy, when the treatment should be stopped, or if it should be done gradually.
Moreover, information regarding the longterm toxicities of sirolimus remains limited.
Conclusion
Sirolimus appears to be effective in children and young adults with complicated VAs. Treatment was tolerated well, with acceptable adverse effects. Further study is needed into early use of sirolimus in cases of low-flow lesions, overgrowth syndromes with low-flow compo nents, and VAs with an overexpression of the mTOR pathway. Topical use of sirolimus in cases of VM with a lymphatic component, such as LVM and CLVM, is both efficient and safe. Although a phase II clinical study was published recently, further prospective studies are needed to evaluate the longterm adverse effect of sirolimus treat ment and to identify highrisk VAs patients presen ting with specific disease phenotypes and/or genotypes, in whom sirolimus is effective and safe.
